drugset / Trial / NCT02106780

A Study to Evaluate the Effect of ASP1707 on the Bodies of Healthy Male Subjects After a Single Dose of Radioactive ASP1707

NCT02106780

Phase 1 Completed 6 enrolled Astellas Pharma Europe B.V.
NaSingle-groupOpen-labelBasic science

Summary

Subjects receive a single oral dose of radioactive ASP1707 on Day 1. Blood, plasma, urine and feces samples are collected for analysis of 14C-radioactivity and ASP1707. Metabolites are collected until at least 144 hours after dosing.

Timeline

Start
2011-08
Primary completion
2011-09
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Subject OPIGOLIX Other / unclassified Oral

Indications

No indication recorded.